EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Liquidia's enterprise value is $925.78 Mil.
Liquidia's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $17.49 Mil. Therefore, Liquidia's EV-to-Revenue for today is 52.94.
The historical rank and industry rank for Liquidia's EV-to-Revenue or its related term are showing as below:
LQDA'
s EV-to-Revenue Range Over the Past 10 Years
Min: 5 Med: 21.12 Max: 132.4
Current: 52.94
During the past 8 years, the highest EV-to-Revenue of Liquidia was 132.40. The lowest was 5.00. And the median was 21.12.
LQDA's EV-to-Revenue is ranked worse than 78.84% of 1035
companies
in the Biotechnology industry
Industry Median: 8.07
vs LQDA: 52.94
As of today (2024-05-03), Liquidia's stock price is $12.98.
Liquidia's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.27. Therefore, Liquidia's PS Ratio for today is 48.25.
Liquidia EV-to-Revenue Historical Data
The historical data trend for Liquidia's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Liquidia's EV-to-Revenue
For the Biotechnology subindustry, Liquidia's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liquidia's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Liquidia's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Liquidia's EV-to-Revenue falls into.
Liquidia's current Enterprise Value is $925.78 Mil.
Liquidia's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liquidia's share price for today is $12.98.
Liquidia's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.27.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liquidia EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Liquidia's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LQDA has been successfully added to your 